Current paradigms for the use of HER2-targeted therapy in early-stage breast cancer.

No abstract is available for this paper.

• Publication year

  2008

• Venue

  Clinical Breast Cancer

• Publication date

  2008-12-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.3816/CBC.2008.s.012PMID 19158036
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Efficacy and Safety of Trastuzumab as a Single Agent in First-Line Treatment of HER2-Overexpressing Metastatic Breast Cancer

  2023cited by this paper
• Phase III Randomized Trial Comparing Doxorubicin and Cyclophosphamide Followed by Docetaxel (AC→T) with Doxorubicin and Cyclophosphamide Followed by Docetaxel and Trastuzumab (AC→TH) with Docetaxel, Carboplatin and Trastuzumab (TCH) in Her2neu Positive Early Breast Cancer Patients: BCIRG 006 Study.

  2009cited by this paper
• Efficacy and safety of lapatinib as first-line therapy for ErbB2-amplified locally advanced or metastatic breast cancer.

  2008cited by this paper
• Cardiac safety analysis of doxorubicin and cyclophosphamide followed by paclitaxel with or without trastuzumab in the North Central Cancer Treatment Group N9831 adjuvant breast cancer trial.

  2008cited by this paper
• HER2 status and benefit from adjuvant trastuzumab in breast cancer.

  2008cited by this paper
• Trastuzumab-related cardiotoxicity in the herceptin adjuvant trial.

  2008cited by this paper
• HER2 status and efficacy of adjuvant anthracyclines in early breast cancer: a pooled analysis of randomized trials.

  2008cited by this paper
• Estimating the magnitude of trastuzumab effects within patient subgroups in the HERA trial.

  2008cited by this paper
• A randomized study of lapatinib alone or in combination with trastuzumab in heavily pretreated HER2+ metastatic breast cancer progressing on trastuzumab therapy

  2008cited by this paper
• Trastuzumab in the adjuvant treatment of early-stage breast cancer: a systematic review and meta-analysis of randomized controlled trials.

  2008cited by this paper
• Randomized, double-blind, placebo-controlled, phase III study of bevacizumab with docetaxel or docetaxel with placebo as first-line therapy for patients with locally recurrent or metastatic breast cancer (mBC): AVADO.

  2008cited by this paper
• Randomized phase III trial of weekly compared with every-3-weeks paclitaxel for metastatic breast cancer, with trastuzumab for all HER-2 overexpressors and random assignment to trastuzumab or not in HER-2 nonoverexpressors: final results of Cancer and Leukemia Group B protocol 9840.

  2008cited by this paper
• Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer.

  2007cited by this paper
• Trastuzumab-associated cardiac adverse effects in the herceptin adjuvant trial.

  2007cited by this paper
• Cardiotoxicity of trastuzumab in clinical practice.

  2007cited by this paper
• CALGB 150002: Correlation of HER2 and chromosome 17 (ch17) copy number with trastuzumab (T) efficacy in CALGB 9840, paclitaxel (P) with or without T in HER2+ and HER2- metastatic breast cancer (MBC)

  2007cited by this paper
• 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial.

  2007cited by this paper
• Updated results of the combined analysis of NCCTG N9831 and NSABP B-31 adjuvant chemotherapy with/without trastuzumab in patients with HER2-positive breast cancer

  2007cited by this paper
• American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer.

  2007cited by this paper
• Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer.

  2006cited by this paper
• Long-term cardiac toxicity after adjuvant epirubicin-based chemotherapy in early breast cancer: French Adjuvant Study Group results.

  2006cited by this paper
• 29th Annual San Antonio Breast Cancer Symposium, December 14-17, 2006, San Antonio, Texas, USA. Abstracts.

  2006cited by this paper
• American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer.

  2006cited by this paper
• Use and outcomes of adjuvant chemotherapy in older women with breast cancer.

  2006cited by this paper
• HER-2 gene amplification by chromogenic in situ hybridisation (CISH) compared with fluorescence in situ hybridisation (FISH) in breast cancer-A study of two hundred cases.

  2006cited by this paper
• Neuregulin-1 beta attenuates doxorubicin-induced alterations of excitation-contraction coupling and reduces oxidative stress in adult rat cardiomyocytes.

  2006cited by this paper
• Kinetics of beta-lactam antibiotics synthesis by penicillin G acylase (PGA) from the viewpoint of the industrial enzymatic reactor optimization.

  2006cited by this paper
• Five year update of cardiac dysfunction on NSABP B-31, a randomized trial of sequential doxorubicin/cyclophosphamide (AC)->paclitaxel (T) vs. AC->T with trastuzumab (H)

  2006cited by this paper
• Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer.

  2005cited by this paper
• Determination of HER2 Gene Amplification by Fluorescence In situ Hybridization and Concordance with the Clinical Trials Immunohistochemical Assay in Women with Metastatic Breast Cancer Evaluated for Treatment with Trastuzumab

  2005cited by this paper
• Chemotherapy and cardiotoxicity in older breast cancer patients: a population-based study.

  2005cited by this paper
• Reversibility of trastuzumab-related cardiotoxicity: new insights based on clinical course and response to medical treatment.

  2005cited by this paper
• Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials.

  2005cited by this paper
• Randomized trial comparing cyclophosphamide, epirubicin, and fluorouracil with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer: update of National Cancer Institute of Canada Clinical Trials Group Trial MA5.

  2005cited by this paper
• Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer.

  2005cited by this paper
• Trastuzumab and vinorelbine as first-line therapy for HER2-overexpressing metastatic breast cancer: multicenter phase II trial with clinical outcomes, analysis of serum tumor markers as predictive factors, and cardiac surveillance algorithm.

  2003cited by this paper
• From evidence-based medicine to clinical practice: not always straightforward

  2003cited by this paper
• American Society of Clinical Oncology educational book

  2003cited by this paper
• Pharmacokinetics, safety, and efficacy of trastuzumab administered every three weeks in combination with paclitaxel.

  2003cited by this paper
• Concordance between local and central laboratory HER2 testing in the breast intergroup trial N9831.

  2002cited by this paper
• Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer.

  2002cited by this paper
• Real-world performance of HER2 testing--National Surgical Adjuvant Breast and Bowel Project experience.

  2002cited by this paper
• The n e w e n g l a n d j o u r n a l of m e d i c i n e

  2001cited by this paper
• Prevalence of left-ventricular systolic dysfunction and heart failure in the Echocardiographic Heart of England Screening study: a population based study.

  2001cited by this paper
• Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

  2001cited by this paper
• Trastuzumab and chemotherapeutics: drug interactions and synergies.

  2000cited by this paper
• Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease.

  1999cited by this paper
• Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer.

  1996cited by this paper
• Risk factors for doxorubicin-induced congestive heart failure.

  1979cited by this paper

• Antioxidant and Anti-Breast Cancer Properties of Hyaluronidase from Marine Staphylococcus aureus (CASMTK1)

  2023cites this paper
• Breast cancer-specific mortality in early breast cancer as defined by high-risk clinical and pathologic characteristics

  2022cites this paper
• Epigenetic modulators combination with chemotherapy in breast cancer cells

  2021cites this paper
• Long Term Trastuzumab in Metastatic Setting of the Patients with HER2Positive Breast Cancer

  2016cites this paper
• Endocrine mucin‐producing sweat gland carcinoma: a study of three cases and CK8, CK18 and CD5/6 immunoexpression

  2015cites this paper
• A Network-Based Model of Oncogenic Collaboration for Prediction of Drug Sensitivity

  2015cites this paper
• Oncogenes and Tumor Suppressor Genes as a Biomarker in Breast Cancer

  2014cites this paper
• Cancer Immunotherapy Using γδT Cells: Dealing with Diversity

  2014cites this paper
• 2 years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer (HERA): an open-label, randomised controlled trial.

  2013cites this paper
• Helping Eve Overcome ADAM: G-Quadruplexes in the ADAM-15 Promoter as New Molecular Targets for Breast Cancer Therapeutics

  2013cites this paper
• years versus 1 year of adjuvant trastuzumab for HER 2-positive breast cancer ( HERA ) : an open-label , randomised controlled trial

  2013cites this paper
• Influência do microambiente no prognóstico do câncer de mama

  2013cites this paper
• Therapeutic antibodies against cancer.

  2012cites this paper
• Therapeutic proteins.

  2012cites this paper
• Evaluation of accuracy in simultaneous dual-radionuclide activity quantification in preclinical instruments – scintillation counter, digital autoradiography and micro-SPECT/CT

  2012cites this paper
• Activity and resistance of trastuzumab according to different clinical settings.

  2012cites this paper
• The Important Molecular Markers on Chromosome 17 and Their Clinical Impact in Breast Cancer

  2011cites this paper
• Novel Toll-like receptor-4 deficiency attenuates trastuzumab (Herceptin) induced cardiac injury in mice

  2011cites this paper
• The HER2 World: Better Treatment Selection for Better Outcome.

  2011cites this paper
• Therapeutic antibodies, vaccines and antibodyomes

  2010cites this paper
• [Adjuvant chemotherapy of early stage breast cancer].

  2010cites this paper
• The Met receptor tyrosine kinase and basal breast cancer

  2010cites this paper
• Recommendations for research priorities in breast cancer by the Coalition of Cancer Cooperative Groups Scientific Leadership Council: systemic therapy and therapeutic individualization

  2010cites this paper
• A gyógyszeres kezelés szerepe a korai emlőrák kezelésében

  2010cites this paper
• Clinical updates on EGFR/HER targeted agents in early-stage breast cancer.

  2010cites this paper
• Structure-Based and Ligand-Based Drug Design for HER 2 Receptor

  2010cites this paper
• Regulatory aspects of oncology drug safety evaluation: past practice, current issues, and the challenge of new drugs.

  2010cites this paper
• Estrogen/progesterone receptor negativity and HER2 positivity predict locoregional recurrence in patients with T1a,bN0 breast cancer.

  2009cites this paper
• Presence of HER4 associates with increased sensitivity to Herceptin™ in patients with metastatic breast cancer

  2009cites this paper
• Molecular pharmacology of voltage-gated sodium channel expression in metastatic disease: clinical potential of neonatal Nav1.5 in breast cancer.

  2009cites this paper
• Drug-induced thrombocytopenia induced by trastuzumab: a special challenge in a curable disease.

  2009cites this paper
• Drug-induced thrombocytopenia induced by trastuzumab: a special challenge in a curable disease

  2009cites this paper
• The use of bevacizumab and trastuzumab beyond tumor progression: a new avenue in cancer treatment?

  2009cites this paper
• Molecular Imaging of HER2 Expression using Synthetic Affibody Molecules : Design, Synthesis and Biological Evaluation

  2009cites this paper